Navigation Links
Peripheral Arterial Disease (PAD) - Pipeline Assessment and Market Forecasts to 2017 Now Available at ReportsandReports
Date:11/1/2010

Peripheral Arterial Disease (PAD) - Pipeline Assessment and Market Forecasts to 2017 Now... -- DALLAS, November 1, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Publishing & Information Services, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Surveys, Polls and Research, Economic News, Trends, Analysis Click to view news release full screen  

Peripheral Arterial Disease (PAD) - Pipeline Assessment and Market Forecasts to 2017 Now Available at ReportsandReports

 

DALLAS, November 1, 2010 /PRNewswire/ -- ReportsandReports announces it will carry Peripheral Arterial Disease (PAD) - Pipeline Assessment and Market Forecasts to 2017 Research Report in its store.

Browse the complete Report on: http://www.reportsnreports.com/Reports/37204-peripheral-arterial-disease-pad- pipeline-assessment-and-marke.html

Browse All Manufacturing & Construction Reports: http://www.reportsnreports.com/market-research/pharmaceuticals/

Browse All GlobalData Research Reports at http://www.reportsnreports.com/publishers/globaldata/

GlobalData, the industry analysis specialist, has released its new report, "Peripheral Arterial Disease (PAD) - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global PAD market. The report identifies the key trends shaping and driving the global PAD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global PAD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The global PAD therapeutics market accounted for approximately $606m in 2009. In 2001, the market was valued at $405m and it grew at an approximate CAGR of 5.2% between 2001 and 2009. The global PAD therapeutics market is expected to reach $1 billion by 2017 growing at a CAGR of 6.5% between 2009 and 2017. The primary factor contributing to the increase in growth over the forecast period is the increase in disease incidence and the launch of new first-in-class drugs. Presently the therapeutic regimen for PAD consists of antiplatelet agents such as clopidogrel (Plavix) and ticlopidine (Ticlid). Blood thinners such as pentoxifyline (Trental) and Cilostazol (Pletal) are also prescribed. Like most cardiovascular complications, aspirin is used as a complementary drug in combination with the above mentioned drugs.

Scope

The report provides information on the key drivers and challenges of the PAD market. Its scope includes: - Annualized global PAD market revenues data from 2001 to 2009, forecast for eight years to 2017. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as of gene therapy, stem cell therapy, platelet aggregation inhibitor, Hydroxymethylglutaryl-CoA reductase inhibitor, monoclonal antibody, micro RNA, protein kinase modulator, Y2 agonist, and PPAR (Peroxisome Proliferator Activated Receptor) agonist. - Analysis of the current and future competition in the global PAD market. Key market players covered are Sanofi Aventis, Indigo pharmaceuticals, BioMarin Pharmaceutical, and AnGes MG Inc. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the PAD therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to: - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global PAD market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global PAD market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What's the next big thing in the global PAD market landscape? - Identify, understand and capitalize.

Browse All Specific Markets: http://www.reportsnreports.com/tagIndex.aspx

Browse All Latest Reports: http://www.reportsnreports.com/LatestReport.aspx

Related Reports

Peripheral Arterial Disease (PAD) - Drug Pipeline Analysis and Market Forecasts to 2016 ( http://www.reportsnreports.com/reports/16053-peripheral-arterial-disease-pad- drug-pipeline-analysis-and-ma.html)

Peripheral Arterial Disease Therapy Area Pipeline Report ( http://www.reportsnreports.com/reports/32464-peripheral-arterial-disease-ther apy-area-pipeline-report.html)

Influenza Vaccines - Pipeline Assessment and Market Forecasts to 2017 (http://www.reportsnreports.com/reports/36584-influenza-vaccines-pipeline-ass essment-and-market-forecasts-to-.html)

Head and Neck Cancer - Pipeline Assessment and Market Forecast to 2017 (http://www.reportsnreports.com/reports/36585-head-and-neck-cancer-pipeline-a ssessment-and-market-forecast-to.html)

Rheumatoid Arthritis - Pipeline Assessment and Market Forecasts to 2017 (http://www.reportsnreports.com/reports/37160-rheumatoid-arthritis-pipeline-a ssessment-and-market-forecasts-t.html)

Systemic Lupus Erythematosus - Pipeline Assessment and Market Forecasts to 2017 ( http://www.reportsnreports.com/reports/37161-systemic-lupus-erythematosus-pip eline-assessment-and-market-for.html)

Anemia - Pipeline Assessment and Market Forecasts to 2017 ( http://www.reportsnreports.com/reports/37162-anemia-pipeline-assessment-and-m arket-forecasts-to-2017.html)

Growth Hormone Deficiency (GHD) - Pipeline Assessment and Market Forecasts to 2017 ( http://www.reportsnreports.com/reports/37205-growth-hormone-deficiency-ghd-pi peline-assessment-and-market-.html)

Type 1 Diabetes - Drug Pipeline Assessment and Market Forecasts to 2017 (http://www.reportsnreports.com/reports/25702-type-1-diabetes-drug-pipeline-a ssessment-and-market-forecasts-t.html)

Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 ( http://www.reportsnreports.com/reports/27388-hormone-replacement-therapy-in-m enopause-pipeline-assessment-an.html)

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)

About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact: Ms. Sunita 7557 Rambler road, Suite 727, Dallas, TX 75231 Tel: +1-888-989-8004 http://www.reportsnreports.com/
'/>"/>

SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Peripheral Artery Disease (PAD) Patent Granted to Dimera
2. CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
3. Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
4. ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons
5. Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
6. Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
7. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
8. Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinsons Disease
9. HumanTouch Expands Services to the Centers for Disease Control and Prevention as a Prime Contract Holder as Part of $1.0 Billion Contract
10. 550 People Across Europe Will Die Today From a Preventable Lung Disease
11. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... RADNOR, Pa., Feb. 24, 2017  VWR Corporation (NASDAQ: VWR), ... to laboratory and production customers, today reported its financial results ... 2016. Highlights: 4Q16 record ... up 1.0% on an organic basis. ... on an organic basis, while the Americas net sales increased ...
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
Breaking Biology Technology:
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
Breaking Biology News(10 mins):